Rational Advisors LLC Has $832,000 Holdings in Merck & Co., Inc. (MRK)

Share on StockTwits

Rational Advisors LLC lessened its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 49.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,713 shares of the company’s stock after selling 13,348 shares during the period. Rational Advisors LLC’s holdings in Merck & Co., Inc. were worth $832,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of MRK. Cobblestone Capital Advisors LLC NY boosted its position in Merck & Co., Inc. by 0.4% during the second quarter. Cobblestone Capital Advisors LLC NY now owns 187,080 shares of the company’s stock worth $11,356,000 after purchasing an additional 774 shares during the period. Checchi Capital Advisers LLC lifted its holdings in shares of Merck & Co., Inc. by 3.0% during the second quarter. Checchi Capital Advisers LLC now owns 26,914 shares of the company’s stock worth $1,634,000 after buying an additional 792 shares during the last quarter. Mckinley Capital Management LLC Delaware lifted its holdings in shares of Merck & Co., Inc. by 5.6% during the second quarter. Mckinley Capital Management LLC Delaware now owns 15,447 shares of the company’s stock worth $938,000 after buying an additional 815 shares during the last quarter. Summit X LLC lifted its holdings in shares of Merck & Co., Inc. by 9.2% during the first quarter. Summit X LLC now owns 10,093 shares of the company’s stock worth $552,000 after buying an additional 850 shares during the last quarter. Finally, Covenant Asset Management LLC lifted its holdings in shares of Merck & Co., Inc. by 1.4% during the second quarter. Covenant Asset Management LLC now owns 62,353 shares of the company’s stock worth $3,785,000 after buying an additional 850 shares during the last quarter. Hedge funds and other institutional investors own 72.18% of the company’s stock.

MRK has been the subject of a number of research analyst reports. Bank of America upped their price target on Merck & Co., Inc. from $70.00 to $74.00 and gave the stock a “buy” rating in a report on Monday, July 30th. Zacks Investment Research upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $80.00 target price for the company in a research note on Monday, October 8th. Morgan Stanley set a $74.00 target price on Merck & Co., Inc. and gave the company a “buy” rating in a research note on Thursday, August 23rd. Jefferies Financial Group restated a “hold” rating and set a $59.00 target price on shares of Merck & Co., Inc. in a report on Sunday, July 15th. Finally, Barclays increased their target price on Merck & Co., Inc. from $70.00 to $75.00 and gave the stock an “overweight” rating in a report on Friday, September 7th. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $69.80.

Shares of NYSE MRK traded up $1.44 during mid-day trading on Friday, reaching $69.81. 9,113,948 shares of the company’s stock were exchanged, compared to its average volume of 10,634,493. The firm has a market cap of $191.27 billion, a P/E ratio of 17.54, a P/E/G ratio of 2.22 and a beta of 0.81. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.33 and a quick ratio of 1.04. Merck & Co., Inc. has a twelve month low of $52.83 and a twelve month high of $72.89.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Friday, July 27th. The company reported $1.06 EPS for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.03. The company had revenue of $10.47 billion for the quarter, compared to analyst estimates of $10.28 billion. Merck & Co., Inc. had a return on equity of 32.68% and a net margin of 3.67%. Merck & Co., Inc.’s revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.01 earnings per share. Equities analysts anticipate that Merck & Co., Inc. will post 4.27 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, October 5th. Shareholders of record on Monday, September 17th were paid a $0.48 dividend. The ex-dividend date of this dividend was Friday, September 14th. This represents a $1.92 dividend on an annualized basis and a yield of 2.75%. Merck & Co., Inc.’s dividend payout ratio is 48.24%.

In related news, VP Rita A. Karachun sold 5,000 shares of Merck & Co., Inc. stock in a transaction that occurred on Thursday, August 2nd. The stock was sold at an average price of $65.01, for a total transaction of $325,050.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman Kenneth C. Frazier sold 279,850 shares of Merck & Co., Inc. stock in a transaction that occurred on Tuesday, October 2nd. The stock was sold at an average price of $72.07, for a total value of $20,168,789.50. Following the sale, the chairman now directly owns 971,800 shares of the company’s stock, valued at $70,037,626. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 929,360 shares of company stock valued at $64,370,599. Corporate insiders own 0.32% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Recommended Story: What strategies should day traders use to execute a trade?

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.